Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

Feb 10 2020

• By Mandy Jackson

Closed up finger on keyboard with word CLINICAL TRIALS — Troriluzole failed in anxiety, but has three other readouts in 2020 and 2021.

Related Content

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

Jul 29 2019

Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status

Jan 23 2020

Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

Jan 27 2020

Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches

Jan 31 2020

Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump

Feb 03 2020

Lundbeck Set For 'Transformative' Eptinezumab Launch

Feb 07 2020

Pipeline Watch: Phase III Starts For Vorasidenib, Tirzepatide, Resmetirom

Dec 20 2019

Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis

Sep 06 2018

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

AstraZeneca PLC

Eli Lilly and Company

Allergan plc

H. Lundbeck A/S

Additional Topics

Clinical Trials Business Strategies Companies Research & Development Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window